Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
14 hedge funds and large institutions have $52.4K invested in Avenue Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
8% more funds holding
Funds holding: 13 → 14 (+1)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
67% less capital invested
Capital invested by funds: $157K → $52.4K (-$105K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$27.7K |
| 2 |
Millennium Management
New York
|
+$8.91K |
| 3 |
HF
HRT Financial
New York
|
+$7.88K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$4.07K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$36.5K |
| 2 |
SAM
Shikiar Asset Management
New York
|
-$9K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$353 |
| 4 |
Morgan Stanley
New York
|
-$195 |
| 5 |
BlackRock
New York
|
-$187 |
ATXI Hedge Fund Activity: Q4 2023 in Review
14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2023, worth a combined $52.4K — down 67% from $157K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ATXI positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $27.7K. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $36.5K sold.
- 14 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2023, up from 13 in Q3 2023.
- Funds reported $52.4K of Avenue Therapeutics, Inc. Common Stock stock for Q4 2023, down 67% quarter-over-quarter.
- 5 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2023 and 4 closed out, a net change of +1 holder.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2023 was Citadel Advisors, an estimated $27.7K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2023 was Bank of New York Mellon, an estimated $36.5K sold.
Based on aggregated 13F filings for Q4 2023.